Related posts
New 52-Week Highs and Lows (Nov 21-27)(A Top Pick Jan 13/14. Down 66.82%.) Had an amazing initial climb based on the clamping of the spinal vertebrae. Probably just had too much of a push. They are now down into the hard work of selling into the hospital systems in the US, which apparently have turned a bit cautious. Have 12 or 13 competitors.
Have been getting clearance for their spinal devices in the US, England and most recently in Canada. They are in the build process, exhibiting patients, working hard to get into the hospitals, and have launched an additional product. Have about 12 competitors. The stock ran too far, right in the beginning. He will continue to hold.
This kind of collapsed in a mysterious way in July. Thinks it went too far, too fast. Wait for the recovery for the company to get its nose and head down and get working on the products, and selling into the US hospital space. Have new products and they are getting serious. Thinks it has now stabilized. Speculatively, it could easily double in the next 12 months.
Medical devices. This is probably one of the better corrections as it has had a phenomenal move. There is a dearth of news on the company. They have FDA approval. Things are kind of slow in hospital orders in the US at the moment. This sounds like an opportunity. A great investment for a retail investor who doesn’t have all that much money.
Aurora Spine is a Canadian stock, trading under the symbol ASG-X on the TSX Venture Exchange (ASG-CV). It is usually referred to as TSXV:ASG or ASG-X
In the last year, there was no coverage of Aurora Spine published on Stockchase.
Aurora Spine was recommended as a Top Pick by on . Read the latest stock experts ratings for Aurora Spine.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
In the last year, there was no coverage of Aurora Spine published on Stockchase.
On 2025-04-17, Aurora Spine (ASG-X) stock closed at a price of $0.3.
It was all " gung ho" about 2 years ago. It is difficult to find out what is going on. Management have been rather shy for a long time. Overall revenues have not risen dramatically for a long time. There are a lot of competitors. He needs to look more closely into the company.